In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Terms of FTC-Mandated Product Divestitures

Executive Summary

As pharmaceutical mega-mergers continue, so too do FTC-driven product divestitures by those merged companies, as businesses that formerly competed in given markets combine into potential monopolies. We look at the terms of some notable product divestitures completed to attain FTC approval of a pending merger.

You may also be interested in...



Your Friend, the FTC: Nastech Solves a Knotty Anti-Trust Problem

When the FTC forced Pfizer/Pharmacia to divest Nastech's nasal apomorphine--a potential competitor of Pfizer's Viagra--Nastech managed what may be a unique solution: it got the product back, with additional financing-and in so doing, solved the very different problems of Pharmacia, Pfizer, the FTC, and itself.

Industry Impact: Siemens Healthineers $16.4Bn Acquisition Of Varian – What Next?

Siemens Healthineers' acquisition of radiation oncology company Varian Medical Systems creates an oncology giant. Analysts disagree on whether its the right move for the companies.

Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus

Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL030495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel